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Evaluation of risk for graft-versus-host disease 
in children who receive less than the full doses 
of mini-dose methotrexate for graft-versus-host 
disease prophylaxis in allogeneic hematopoietic 
stem cell transplantation
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Purpose: The use of cyclosporine and mini-dose methotrexate (MTX) is a common strategy for graft-
versus-host disease (GVHD) prophylaxis in allogeneic transplants. We investigated whether patients 
who receive fewer than the planned MTX doses are at increased risk for GVHD.
Methods: The study cohort included 103 patients who received allogeneic transplants at the 
Department of Pediatrics of The Catholic University of Korea College of Medicine, from January 2010 
to December 2011. MTX was administered on days 1, 3, 6, and 11 after transplant at a dose of 5 mg/
m
2 each. Within the cohort, 76 patients (74%) received all 4 doses of MTX [MTX(4) group], while 27 
patients (26%) received 0–3 doses [MTX(0–3) group].
Results: Although there was no difference in neutrophil engraftment between the 2 groups, platelet 
engraftment was significantly faster in the MTX(4) group (median, 15 days), compared to the MTX(0–
3) group (median, 25 days; P=0.034). The incidence of grades II–IV acute GVHD was not different 
between the MTX(4) and MTX(0–3) groups (P=0.417). In the multivariate study, human leukocyte 
antigen mismatch was the most significant factor causing grades II–IV acute GVHD (P=0.002), 
followed by female donor to male recipient transplant (P=0.034). No difference was found between the 
MTX(4) and MTX (0–3) groups regarding grades III–IV acute GVHD, chronic GVHD, and disease-free 
survival. 
Conclusion: Our results indicate that deviations from the full dose schedule of MTX for GVHD 
prophylaxis do not lead to increased incidence of either acute or chronic GVHD.
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Introduction
Both acute and chronic graft-versus-host disease (GVHD) are significant complications 
that may occur in children who receive allogeneic hematopoietic stem cell transplantation 
(HSCT), although the overall incidence is lower than found in the adult patient 
population
1,2). As methods of treating GVHD are limited once it is diagnosed, a significant 
emphasis is on the prevention of GVHD. Such strategies for prevention may gain greater 
attention with recent increasing use of unrelated donors and other alternative donors for 
HSCT.491 http://dx.doi.org/10.3345/kjp.2013.56.11.490
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Since its initial introduction in 1986, a combination of cyclo-
sporine (CsA) and mini-dose methotrexate (MTX) has become an 
important means of GVHD prophylaxis
3,4). This regimen resulted 
in lower rates of GVHD when compared to prophylaxis with 
CsA alone in patients who received HSCT for both malignant 
and nonmalignant disease
5,6). Of note, this immunosuppressive 
combination has also shown efficacy in children who receive 
allogeneic transplant
7).
In this GVHD prophylaxis regimen, 4 doses of MTX are given 
on days 1, 3, 6, and 11 after transplant. However, 1 or more of 
these MTX doses are often omitted if the patient shows signs 
and symptoms of significant mucositis that requires analgesia, 
or if there is evidence of hepatic or renal toxicity. The overall 
effect of these omissions on subsequent acute and chronic 
GVHD incidence remains unclear. An earlier study showed 
that omission of the final day 11 MTX did not adversely affect 
incidence of severe acute GVHD and chronic GVHD
8), while 2 
later reports showed a greater risk for GVHD in patients who 
were not given all planned doses of MTX
9,10). The majority of 
the patients in these 3 reports were adult recipients of HSCT. 
As the incidence and severity of GVHD tends to be lower in 
pediatric patients compared with adults, omissions from the full 
schedule of prophylactic MTX may result in different outcomes 
in children.
Our main objective in this study was to compare the incidence 
of acute and chronic GVHD, and survival between pediatric 
patients who received the full schedule of mini-dose MTX and 
patients who were given less than the full schedule, in order to 
verify the effect of these MTX omissions on important transplant 
outcomes.
Materials and methods
1. Study cohort
The study cohort included 103 patients who received allo-
geneic HSCT at the Department of Pediatrics, The Catholic 
University of Korea College of Medicine during a period of 2 
years from January, 2010 to December, 2011 (Table 1).
2. Transplantation procedure
Donor-recipient pairs were matched at human leukocyte 
antigen (HLA)-A, B, C, and DRB1 alleles using high resolution 
typing. Children who were treated for malignant disease 
received either a total body irradiation (TBI)-based or busulfan-
based myeloablative conditioning regimen, while patients who 
received HSCT for bone marrow failure received a fludarabine-
cyclophosphamide based conditioning regimen.
Planned GVHD prophylaxis was uniform and consisted of CsA 
and mini-dose MTX. CsA was started on day-1 intravenously (IV) 
at a dosage of 3 mg/kg/day, which was subsequently switched to 
an oral formulation at 5 mg/kg/day once oral intake was possible. 
Mini-dose MTX was given IV at a dose of 5 mg/m
2/day on days 1, 
3, 6, and 11 posttransplant. Patients who received transplant from 
an unrelated donor, haploidentical family donor, or who were 
transplanted for bone marrow failure received antithymocyte 
globulin (ATG, Thymoglobulin; Genzyme, Cambridge, MA, USA) 
(n=85, 83%). ATG was given at a total dose of 7.5 mg/kg as part 
of the conditioning regimen prior to transplantation, and was 
increased to 10 mg/kg for recipients of haploidentical transplants. 
One or more of the MTX doses was omitted if the patient showed 
signs of mucositis that required narcotic analgesia, at the 
Table 1. Main characteristics of the study cohort (n=103)
Characteristic  Value
Age at transplant (yr)
   Median (range) 9.3 (0.4–23.2)
Gender
   Male/female 60 (58)/43 (42)
Diagnosis
   ALL/AML 25 (24)/32 (31)
   CML/JMML 2 (2)/3 (3)
   MDS/NHL 1 (1)/1 (1)
   HLH/CAEBV/LCS 4 (4)/1 (1)/1 (1)
   SAA/FA 26 (25)/5 (5)
   CDA/KD 1 (1)/1 (1)
Donor type
   Sibling/unrelated/haploidentical 25 (24)/66 (64)/12 (12)
Cell source
   BM/PBSC 14 (14)/89 (86)
HLA compatibility
   Match/mismatch 64 (62)/39 (38)
Donor-recipient gender
   Female-male/others 22 (21)/81 (79)
ABO compatibility
   Match/mismatch 46 (45)/57 (55)
Conditioning regimen
   TBI based/non-TBI based 24 (23)/79 (77)
   With ATG/without ATG 85 (83)/18 (18)
MTX doses
   MTX(4)/MTX(0–3) 76 (74)/27 (26)
Values are presented as number (%) unless otherwise indicated.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, 
chronic myeloid leukemia; JMML, juvenile myelomonocytic leukemia; MDS, 
myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; HLH, hemophagocytic 
lymphohistiocytosis; CAEBV, chronic active Epstein-Barr virus infection; LCS, 
Langerhans cell sarcoma; SAA, severe aplastic anemia; FA, Fanconi anemia; 
CDA, congenital dyserythropoietic anemia; KD, Kostmann disease; BM, bone 
marrow; PBSC, peripheral blood stem cells; HLA, human leukocyte antigen; TBI, 
total body irradiation; ATG, antithymocyte globulin; MTX, methotrexate.http://dx.doi.org/10.3345/kjp.2013.56.11.490
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discretion of the physician responsible for each respective patient. 
Antimicrobial prophylaxis was done as previously published
11).
3. Study endpoints
Posttransplantation outcomes that were evaluated included 
neutrophil and platelet engraftment, acute GVHD grades II–IV, 
acute GVHD grades III–IV, chronic GVHD, disease-free survival 
(DFS), and overall survival (OS). Date of neutrophil engraftment 
was defined as the first of three consecutive days with absolute 
neutrophil count>1.0×10
9/L, and the date of platelet engraftment 
was defined as the first of three consecutive days with platelet 
count>50×10
9/L without platelet transfusions in the preceding 
week. Acute and chronic GVHD were diagnosed and graded 
according to previously published criteria
12,13).
 The following variables were studied for possible predictive 
value with regards to acute and chronic GVHD: number of 
MTX doses infused (4 doses of MTX [MTX(4)] vs. 0–3 doses of 
MTX [MTX(0–3)]), patient age (<10 years old vs. ≥10 years old), 
and gender, underlying disease (malignancy vs. nonmalignant 
disease), donor-recipient HLA compatibility (full match vs. 
mismatch), cell source (bone marrow vs. peri pheral blood stem 
cells), conditioning regimen (TBI based vs. non-TBI based), 
donor-recipient gender (female to male vs. others), ABO 
compatibility, and infused CD34+ and CD3+ cell dose divided 
into 3 equal groups. In addition, antecedent acute GVHD was 
studied for prognostic significance with regards to chronic 
GVHD.
4. Statistical analysis
Comparison of neutrophil and platelet engraftment between 
the MTX(4) and MTX(0–3) groups was done with the Mann-
Whitney test. The impact of independent variables on acute 
and chronic GVHD was done with the cumulative incidence 
function and Gray test for univariate study. For acute GVHD, 
death before day 100 was considered a competing risk, while for 
chronic GVHD death before 1 year was considered a competing 
risk. Multivariate study was done with factors having P<0.1 in 
univariate study, and was calculated according to Fine and Gray 
semiparametric proportional hazards model
14). DFS and OS were 
calculated using the Kaplan-Meier method and comparisons 
made with the log-rank test. Patients alive were censored at date 
of last follow-up, but no later than April 30th, 2013. SPSS ver. 
16 (SPSS Inc., Chicago, IL, USA), and R package ver. 2.14.2 (R 
foundation for Statistical Computing, Vienna, Austria). P<0.05 
were considered statistically significant.
Results
1. MTX dosing
Within the study cohort, 76 patients (74%) received all MTX(4) 
while 27 patients (26%) received MTX(0–3). Of the patients who 
received less than the scheduled MTX doses, 19 patients received 
3 doses (18%), 4 patients received 2 doses (4%), 3 patients 
received 1 dose (3%), and 1 patient did not receive MTX (1%). 
The reason for omission of scheduled MTX in these patients was 
severe oral mucositis in all cases.
2. Cell infusion and neutrophil and platelet engraftment
The medians of infused cell counts were as follows: TNC 
16.7×10
8/kg (range, 1.4–89.7×10
8/kg), MNC 11.4×10
8/kg (range, 
0.5–52.6×10
8/kg), CD34+ 7.8×10
6/kg (range, 1.6–53.4×10
6/kg), 
and CD3+ 63.8×10
7/kg (range, 1.6–284.3×10
7/kg). All patients 
showed neutrophil engraftment at a median of 12 days (range, 
9–27 days), while 96 patients (93%) showed platelet engraftment 
at a median of 17 days (range, 7–258 days). No difference in time 
to neutrophil engraftment was observed between the MTX(4) 
and MTX(0–3) groups (median, 12 days for both groups), while 
platelet engraftment was significantly faster at a median of 15 
days in the MTX(4) group, compared to 25 days for the MTX(0–3) 
group (P=0.034) (Table 2).
3. Acute GVHD grades II–IV
Overall cumulative incidence of grades II–IV acute GVHD was 
49.5%±5.0% (51/103). In univariate study, HLA mismatch (P= 
0.002), female donor to male recipient transplant (P=0.054), and 
higher infused CD3+ cell dose (P=0.029) proved to be important 
(Table 3).  In contrast, the number of MTX doses infused did 
not have significance with regards to grades II–IV acute GVHD 
(P=0.417). In multivariate study, HLA compatibility was the 
most significant factor for predicting grades II–IV acute GVHD 
(P=0.002) followed by donor-recipient gender (P=0.034) (Table 4).
4. Acute GVHD grades III–IV
Overall incidence of severe acute GVHD (grades III–IV) was 
Table 2. Time for neutrophil and platelet engraftment according to the number of MTX doses infused
MTX(4) MTX(0–3)
P value
No. of patients with engraftment (%) Day, median (range) No. of patients with engraftment (%) Day, median (range)
ANC   76 (100) 12 (10–27)   27 (100) 12 (9–18) 0.553
Platelet 73 (96) 15 (7–153) 23 (85) 25 (11–258) 0.034
ANC, absolute neutrophil count; MTX, methotrexate; MTX(4), 4 doses of MTX; MTX(0-3), 0–3 doses of MTX.493 http://dx.doi.org/10.3345/kjp.2013.56.11.490
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7.8%±2.7% (8/103), including 6 patients with grade III and 2 
pa tients with grade IV acute GVHD. None of the studied factors 
proved to be significant with regards to predicting grades III-IV 
acute GVHD. Specifically, the doses of MTX infused did not have 
an impact on grades III–IV acute GVHD (P=0.429). One of the 8 
patients died of causes related to GVHD.
5. Chronic GVHD
The incidence of chronic GVHD was 29.1%±4.5% (30/103), 
including 4 patients with limited and 26 patients with extensive 
chronic GVHD. In univariate study, recipients of 0–3 doses of 
MTX (P=0.034), female gender (P=0.072), malignant disease (P= 
0.074), and preceding acute GVHD (P=0.098) were important 
factors for chronic GVHD incidence. However, none of these fac-
tors were significant in multivariate study. None of the patients 
died from chronic GVHD-related causes in underlying disease 
remission.
6. Survival
The DFS for the cohort was 57.6%±5.4% (63/103). No 
difference in DFS was found between the MTX(4) and MTX(0-
3) groups (56.7%±6.3% and 62.6%±9.4% respectively, P=0.939) 
(Fig. 1).
The OS for the cohort was 68.8%±5.2% (74/103). Twenty-
five patients (24%) died in relapsed disease state. The cause of 
nonrelapse death for the remaining 4 patients was as follows: 
acute GVHD (n=1), cytomegalovirus encephalitis and cerebral 
aspergillosis (n=1), hepatic veno-occlusive disease (n=1), and 
acute respiratory distress syndrome (n=1).
Discussion
Although MTX infusion posttransplantation has been linked 
to delayed engraftment
15), we found no difference in neutrophil 
engraftment between the MTX(4) and MTX(0–3) groups in our 
study. Furthermore, platelet engraftment was significantly faster 
in recipients of the complete MTX schedule compared with 
patients who received less than four doses. The reasons for the 
disparity in platelet engraftment are not clear, but the severe oral 
Table 3. Univariate study of risk factors for grades II–IV acute GVHD
Variable Patient Event P value
MTX doses
   MTX(4)/MTX(0–3) 76/27 36/15 0.417
Patient age (yr)
   <10/≥10 55/48 27/24 0.891
Gender
   Male/female 60/43 30/21 0.983
Disease
   Malignancy/nonmalignancy 69/34 35/16 0.971
Cell source
   BM/PBSC 14/89 5/46 0.356
HLA compatibility
   Match/mismatch 64/39 25/26 0.002
Donor-recipient gender
   Female to male/others 22/81 15/36 0.054
ABO compatibility
   Match/mismatch 46/57 22/29 0.956
Conditioning regimen
   TBI based/non-TBI based 24/79 13/38 0.967
CD34 dose
   <5.5/5.5–12/>12 35/35/33 16/17/18 0.780
CD3 dose
   <45/45–90 />90 33/37/33 16/13/22 0.029
GVHD, graft-versus-host disease; MTX, methotrexate; MTX(4), 4 doses of MTX; 
MTX(0-3), 0–3 doses of MTX; BM, bone marrow; PBSC, peripheral blood stem 
cells; HLA, human leukocyte antigen; TBI, total body irradiation.
Table 4. Multivariate study of risk factors for grades II–IV acute GVHD
Factor Hazard ratio (95% CI) P value
HLA compatibility 0.002
   Match  1
   Mismatch 2.34 (1.36–4.02)
Donor-recipient gender 0.034
   Others 1
   Female to male 1.87 (1.05–3.34)
GVHD, graft-versus-host disease; CI, confidence interval; HLA, human 
leukocyte antigen.  
   MTX(0-3): 62.6%±9.4% (17/27)     
   MTX(4): 56.7%±6.3% (46/76)     
P=0.939   
Fig. 1. Disease-free survival (DFS) according to the number of mini-
methotrexate (MTX) doses infused. The bold line shows DFS for 
recipients of all 4 doses. Dashed line shows the DFS for recipients of 0–3 
doses.http://dx.doi.org/10.3345/kjp.2013.56.11.490
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mucositis, which was a common characteristic of the MTX(0–3) 
group may have led to other posttransplant complications that 
resulted in delayed platelet recovery.
Our results indicate that infusion of less than the complete 
schedule of mini-dose MTX has no effect on outcomes such as 
acute and chronic GVHD, and survival. One or more of the doses 
of MTX are often omitted due to severe mucositis occurring after 
conditioning, or due to hepatic or renal impairment during this 
period. Oral mucositis is a major complication of the immediate 
posttransplantation period that is both difficult to treat and is a 
significant impediment to adequate enteral intake
16,17). As MTX 
infusion itself may cause or aggravate mucositis
18), continued 
adherence to the full MTX dosing schedule is difficult in patients 
with signs and symptoms of severe mucositis. We conclude that 
in such situations doses of MTX may be omitted to allow for 
rapid improvement of mucositis without untoward effects on 
either GVHD or survival.
In our study, the overall incidence of grades II–IV acute GVHD 
(49.5%) was significantly higher than has been reported for 
pediatric transplant cohorts
19). The reasons for the increased rate 
of acute GVHD are not clear, but the large number of alternative 
donor transplants that were undertaken most likely contributed 
to this increased incidence. Donor-recipient HLA compatibility 
proved to be an important factor for acute GVHD incidence, as 
has been reported previously
20). Increased rate of chronic GVHD 
in female donor-male recipient transplants has been reported
21), 
and the importance of this specific gender disparity as a factor 
for acute GVHD in our study underscores its potential role as a 
risk factor for GVHD overall. Despite the high rate of grades II–
IV acute GVHD, the rate of grades III–IV GVHD which are more 
resistant to treatment was low (7.8%), so that we were unable to 
conclude upon significant predictors for this more problematic 
type of GVHD.
The major limitations of our study are as follows; first, the 
number of patients who did not receive all 4 MTX doses was 
much less than patients who completed scheduled dosing. As 
a result, we were unable to divide the patient cohort according 
to the specific number of MTX doses received, but combined 
these patients into one group. Much of previous literature on 
this topic focused on differences in outcome when the final 
fourth MTX dose was omitted only, with one study concluding 
on no difference in incidence of acute GVHD grades II–IV and 
chronic GVHD between patients who received the complete 
MTX schedule and patients in whom the fourth dose was 
omitted
8), while another study found a greater risk for severe 
acute GVHD (grades III–IV) in patients who did not receive the 
fourth dose of MTX
9). In our study, as all patients who received 
less than the complete schedule were placed in one group, the 
effect of a specific MTX omission on outcomes remains unclear. 
Finally, we stress that the majority of patients received ATG as 
part of the conditioning regimen, and its use may have affected 
GVHD incidence. Recent studies indicate that in vivo T-cell 
depletion using ATG is effective in preventing GVHD in children 
who receive unrelated transplants
22,23).  Hence, the comparable 
outcomes observed between the MTX(4) and MTX(0-3) groups 
in our study may have been influenced by the use of ATG, and 
the results herein may be limited to the setting of ATG-based T- 
cell depletion. A question to pursue, then, is whether CsA alone 
is sufficient for GVHD prophylaxis when ATG is also used, a 
notion which is contrary to at least 1 study which showed that 
a 1 drug regimen of prophylaxis (that is, either CsA or MTX) is a 
risk factor for severe acute GVHD in children
24).
In conclusion, our study in a cohort of children who received 
allogeneic transplant indicates that omissions from the full dose 
of mini-MTX for GVHD prophylaxis due to severe patient oral 
mucositis are not detrimental in terms of either GVHD incidence 
or survival. These results should aid in clinical decision making 
with regards to MTX dosing, and possibly allow for faster 
patient recovery from oral mucositis and lower mucositis-related 
morbidity.
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